A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).

Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer

“…Complete pathologic response rates observed with split schedule cisplatin in this study (17.5%) are similar to those in a recent multicenter, prospective trial of dose-dense GC (15%) in which patients received gemcitabine 2,500 mg/m 2 on day 1 and cisplatin 35 mg/m 2 on days 1 and 2 every 2 weeks [7]. However, these response rates should be viewed within the context of historical response rates from transurethral resection alone with immediate cystectomy (15%) [2], ddMVAC using CS cisplatin (26%-43%) [8], and from neoadjuvant immunotherapy (29%-32%) [9,10].…”

The promise and challenges of neoadjuvant immunotherapy in the management of non‐metastatic muscle‐invasive bladder cancer

“…Currently, several trials on the efficacy and safety of ICPI for MIBC are in progress (Table ). Both, the PURE‐01 (Neoadjuvant Pembrolizumab for Muscle‐invasive Urothelial Bladder Carcinoma) and the ABACUS (Preoperative Azetolizumab in Muscle‐invasive Transitional Cell Carcinoma of the Bladder) trials have reported complete response rates (40% and 29%, respectively) using a shorter duration single‐agent neoadjuvant ICPI strategy . These promising results were achieved with two to three doses of ICPI, so that there would be no delay of the planned RC.…”

Nur die Chirurgie? Multimodalkonzepte mit kurativer Intention für das Urothelkarzinom der Harnblase

“…Auch für Nivolumab plus GC wurde eine hohe CR-Rate von 49 % auf dem gleichen Symposium vorgestellt (BLASST-1 Trial). Für Atezolizumab, einen PD-L1-Inhibitor, wurde in einer weiteren Phase II-Studie (ABACUS) ebenfalls in der neoadjuvanten Therapiesituation ein gutes Ansprechen mit hoher Downstaging-Rate gezeigt (CR: 29 %) [87]. Für die adjuvante Anwendung von Atezolizumab (IMvigor 010-Studie) wurde kürzlich seitens des Herstellers in einer Pressemitteilung verkündet, dass der primäre Studienendpunkt (Verbesserung des DFS) nicht erreicht wurde.…”